BACKGROUND: WHO drug-resistant TB (DR-TB) treatment recommendations now emphasize all-oral regimens, recommending against certain injectable agents and deprioritizing others due to inferior safety and efficacy. Despite increasing focus on patient-centered care, we are not aware of systematic attempts to qualitatively document patients' perspectives on injectable agents. This may inform implementation of WHO guidelines, emphasizing the importance of consultation with affected communities. METHODS: Testimonies were provided by TB survivors who experienced hearing loss from treatment with injectable agents. Testimonies were submitted in writing in response to minimal, standardized, open-ended prompts. Participants provided a signed consent form (with options to participate anonymously or as a named co-author), and later gave input into the overall shape and recommendations of the article. RESULTS: Fourteen TB survivors in 12 countries contributed testimonies. The following common themes emerged: lack of access to appropriate testing, information, treatment, or a collaborative treatment environment; the power of supportive care and social environments; stigma and isolation from TB treatment itself and resultant disability; and inaccessibility of cochlear implants. CONCLUSIONS: Survivor testimonies indicate strong preferences for avoidance of injectable agents, supporting rapid implementation of revised WHO guidelines, as well as for quality and supportive care for both TB and disabilities.
BACKGROUND: WHO drug-resistant TB (DR-TB) treatment recommendations now emphasize all-oral regimens, recommending against certain injectable agents and deprioritizing others due to inferior safety and efficacy. Despite increasing focus on patient-centered care, we are not aware of systematic attempts to qualitatively document patients' perspectives on injectable agents. This may inform implementation of WHO guidelines, emphasizing the importance of consultation with affected communities. METHODS: Testimonies were provided by TB survivors who experienced hearing loss from treatment with injectable agents. Testimonies were submitted in writing in response to minimal, standardized, open-ended prompts. Participants provided a signed consent form (with options to participate anonymously or as a named co-author), and later gave input into the overall shape and recommendations of the article. RESULTS: Fourteen TB survivors in 12 countries contributed testimonies. The following common themes emerged: lack of access to appropriate testing, information, treatment, or a collaborative treatment environment; the power of supportive care and social environments; stigma and isolation from TB treatment itself and resultant disability; and inaccessibility of cochlear implants. CONCLUSIONS: Survivor testimonies indicate strong preferences for avoidance of injectable agents, supporting rapid implementation of revised WHO guidelines, as well as for quality and supportive care for both TB and disabilities.
Authors: James A Seddon; Peter Godfrey-Faussett; Kayleen Jacobs; Adam Ebrahim; Anneke C Hesseling; H Simon Schaaf Journal: Eur Respir J Date: 2012-06-14 Impact factor: 16.671
Authors: A Reuter; P Tisile; D von Delft; H Cox; V Cox; L Ditiu; A Garcia-Prats; S Koenig; E Lessem; R Nathavitharana; J A Seddon; J Stillo; A von Delft; J Furin Journal: Int J Tuberc Lung Dis Date: 2017-11-01 Impact factor: 2.373
Authors: Sudeepa Khanal; Helen Elsey; Rebecca King; Sushil C Baral; Bharat Raj Bhatta; James N Newell Journal: PLoS One Date: 2017-01-18 Impact factor: 3.240
Authors: Tae Won Yang; Hyun Oh Park; Ha Nee Jang; Jun Ho Yang; Sung Hwan Kim; Seong Ho Moon; Joung Hun Byun; Chung Eun Lee; Jong Woo Kim; Dong Hun Kang Journal: Medicine (Baltimore) Date: 2017-07 Impact factor: 1.889
Authors: Tembeka Sineke; Denise Evans; Kathryn Schnippel; Heleen van Aswegen; Rebecca Berhanu; Nozipho Musakwa; Elisabet Lönnmark; Lawrence Long; Sydney Rosen Journal: Health Qual Life Outcomes Date: 2019-05-31 Impact factor: 3.186